Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Fosun Pharma’s Drive Beyond China · 17 Nov 2025 podcast

But obviously, then everything changed and moved up.

So what's been driving that from your perspective?

I know you're not necessarily a

you know, a banking space, but at least you know the industry.

And then as you answer that, please tell us a little bit about what you think is the most, what are the most misunderstood aspects of China biotech pharma?

Because the Western friends of mine love to question the quality of data, et cetera, et cetera.

Maybe you can set that straight.

And so the last thing I wanted to ask you, what are the key advantages of start?

I mean, phase threes at the end of the day and bridging studies have to be done in their country that or at least, you know, if you want if you wanted a U.S.

product wanting to come to China, they have to show that they work in Chinese population because of the obvious differences in genetics and environment, etc.,

But in the earlier stages, would you say, I don't want to put words in your mouth, what do you think is one of the key advantages of Fazelli Incorporated wants to bring his drug to development into phase one?

What is the advantage that China offers specifically?

And that's probably where at least the proof of concept is there.

And of course, in terms of development, are you telling me that your Chinese colleagues work 24-7, therefore their productivity is higher?

No.

Oh, gosh.

I'm glad I didn't have to work there.

Anyway, Xing Li, this has been fantastic.

Thank you very much.

Any final words from you?

Showing 681–700 of 906 · page 35 of 46